The landscape of mRNA nanomedicine
Messenger RNA (mRNA) is an emerging class of therapeutic agent for the prevention and
treatment of a wide range of diseases. The recent success of the two highly efficacious …
treatment of a wide range of diseases. The recent success of the two highly efficacious …
[HTML][HTML] SARS-CoV-2 viral load and shedding kinetics
SARS-CoV-2 viral load and detection of infectious virus in the respiratory tract are the two
key parameters for estimating infectiousness. As shedding of infectious virus is required for …
key parameters for estimating infectiousness. As shedding of infectious virus is required for …
A bivalent omicron-containing booster vaccine against Covid-19
S Chalkias, C Harper, K Vrbicky… - … England Journal of …, 2022 - Mass Medical Soc
Background The safety and immunogenicity of the bivalent omicron-containing mRNA-
1273.214 booster vaccine are not known. Methods In this ongoing, phase 2–3 study, we …
1273.214 booster vaccine are not known. Methods In this ongoing, phase 2–3 study, we …
The role of lipid components in lipid nanoparticles for vaccines and gene therapy
CH Albertsen, JA Kulkarni, D Witzigmann… - Advanced drug delivery …, 2022 - Elsevier
Lipid nanoparticles (LNPs) play an important role in mRNA vaccines against COVID-19. In
addition, many preclinical and clinical studies, including the siRNA-LNP product, Onpattro® …
addition, many preclinical and clinical studies, including the siRNA-LNP product, Onpattro® …
Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs
SA Dilliard, DJ Siegwart - Nature Reviews Materials, 2023 - nature.com
Genetic drugs based on nucleic acid biomolecules are a rapidly emerging class of
medicines that directly reprogramme the central dogma of biology to prevent and treat …
medicines that directly reprogramme the central dogma of biology to prevent and treat …
The clinical progress of mRNA vaccines and immunotherapies
The emergency use authorizations (EUAs) of two mRNA-based severe acute respiratory
syndrome coronavirus (SARS-CoV)-2 vaccines approximately 11 months after publication of …
syndrome coronavirus (SARS-CoV)-2 vaccines approximately 11 months after publication of …
mRNA-based therapeutics: powerful and versatile tools to combat diseases
S Qin, X Tang, Y Chen, K Chen, N Fan… - Signal transduction and …, 2022 - nature.com
The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat a wide
range of incurable diseases. Recent rapid advances in biotechnology and molecular …
range of incurable diseases. Recent rapid advances in biotechnology and molecular …
Unlocking the promise of mRNA therapeutics
E Rohner, R Yang, KS Foo, A Goedel… - Nature biotechnology, 2022 - nature.com
The extraordinary success of mRNA vaccines against coronavirus disease 2019 (COVID-19)
has renewed interest in mRNA as a means of delivering therapeutic proteins. Early clinical …
has renewed interest in mRNA as a means of delivering therapeutic proteins. Early clinical …
Advances in COVID-19 mRNA vaccine development
E Fang, X Liu, M Li, Z Zhang, L Song, B Zhu… - Signal transduction and …, 2022 - nature.com
To date, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …
Therapeutically harnessing extracellular vesicles
The field of extracellular vesicle (EV) research has developed rapidly over the last decade
from the study of fundamental biology to a subject of significant clinical relevance. The …
from the study of fundamental biology to a subject of significant clinical relevance. The …